The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Treatment of Opioid-Use Disorders
Open accessAbstract
T his article provides an overview of the current treatment of opioid-related conditions, including treatments provided by general practitioners and by specialists in substance-use disorders.The recent dramatic increase in misuse of prescription analgesics, the easy accessibility of opioids such as heroin on the streets, and the epidemic of opioid overdoses underscore how important it is for physicians to understand more about these drugs and to be able to tell patients about available treatments for substance-use disorders.Opioids include most prescription analgesics as well as products of the poppy plant (e.g., opium, morphine, and codeine).1 Although opioids usually are prescribed to control pain, diminish cough, or relieve diarrhea, they also produce feelings of euphoria, tranquility, and sedation that may lead the patient to continue to take these drugs despite the development of serious related problems.These problems include the need to escalate doses in order to achieve these desired effects; such levels of opioids can overwhelm respiratory drive and lead to death.1,2 Opioid-use disorders are seen in persons from all educational and socioeconomic backgrounds.Recognition of such disorders has contributed to efforts to change physicians' prescribing practices and to train first responders regarding the parenteral administration of naloxone (Narcan or Evzio), a mu-opioid receptor antagonist. 2 In the United States, an estimated 400,000 persons have used heroin in the past month and 4 million have reported nonmedical use of prescription pain relievers.[3][4][5] By some estimates, almost 17,000 deaths per year are related to opioids; drug poisoning is one of the leading causes of accidental death in the United States.Approximately 3 million persons in the United States and almost 16 million worldwide have a current or past opioid-use disorder.6 The global burden of disease from opioid-related conditions approaches 11 million life-years lost from health problems, disabilities, and early death.7 In the 2013 Diagnostic and Statistical Manual of Mental Disorders of the American Psychiatric Association (Table 1), an opioid-use disorder is defined as the repeated occurrence within a 12-month period of 2 or more of 11 problems, including withdrawal, giving up important life events in order to use opioids, and excessive time spent using opioids.A cluster of 6 or more items indicates a severe con dition.4,8 The clinical course of opioid-use disorders involves periods of exacerbation and remission, but the underlying vulnerability never disappears. 1 This pattern is similar to that of other chronic relapsing conditions (e.g., diabetes and hypertension) in which perfect control of symptoms is difficult and patient adherence to treatment is often incomplete.Although persons with opioid problems are likely to have extended periods of abstinence from opioids and often do well, 9 the risk of early death, primarily from an accidental overdose, trauma, suicide, or an infectious disease (e.g., human immunodeficiency virus [HIV] infection), is increased by a factor of 20. [10][11][12][13][14][15] Legal problems are especially likely in persons with criminal records and high impulsivity.13 The risk of adverse outcomes decreases markedly with abstinence from opioids.9,16
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“A key component of OUD is the development of long-lasting drug craving (3–5), whether in the context of prescribed opioids, such as for analgesic purposes, or illicitly acquired heroin.”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [5]
In the citing paper
“Inhibition of craving has long been a goal of OUD treatment (5).”
From Craving in Opioid Use Disorder: From Neurobiology to Clinical Practice (2019) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Diagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence
Mattick, R. P., Breen, C., Kimber, J., & Davoli, M. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002207.pub4 · Cited by 2,274
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Dutra, L., Stathopoulou, G., Basden, S. L., Leyro, T. M., Powers, M. B., & Otto, M. W. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.06111851 · Cited by 1,287
Trends in Opioid Analgesic Abuse and Mortality in the United States
Dart, R. C., Surratt, H. L., Cicero, T. J., Parrino, M. W., Severtson, S. G., Bucher-Bartelson, B., & Green, J. L. (2015) · New England Journal of Medicine · doi:10.1056/nejmsa1406143 · Cited by 1,137
The Clinical Opiate Withdrawal Scale (COWS)
Wesson, D. R., & Ling, W. (2003) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2003.10400007 · Cited by 1,120
D’Onofrio, G., O’Connor, P. G., Pantalon, M. V., Chawarski, M. C., Busch, S. H., Owens, P. H., Bernstein, S. L., & Fiellin, D. A. (2015) · JAMA · doi:10.1001/jama.2015.3474 · Cited by 910
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 712
VASILAKI, E. I., HOSIER, S. G., & COX, W. M. (2006) · Alcohol and Alcoholism · doi:10.1093/alcalc/agl016 · Cited by 581
A Systematic Review of Community Opioid Overdose Prevention and Naloxone Distribution Programs
Clark, A. K., Wilder, C. M., & Winstanley, E. L. (2014) · Journal of Addiction Medicine · doi:10.1097/adm.0000000000000034 · Cited by 488
Hser, Y., Saxon, A. J., Huang, D., Hasson, A., Thomas, C., Hillhouse, M., Jacobs, P., Teruya, C., McLaughlin, P., Wiest, K., et al. (2014) · Addiction · doi:10.1111/add.12333 · Cited by 455
Research works printed but not linked: 8
- O’Brien CP. Drug addiction. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011:649-666.
- 2012, MMWR Morb Mortal Wkly Rep, 61, 133
- Gowing L, 2014, Cochrane Database Syst Rev, 3, CD002024
- Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton L, Chabner B, Knollman B, eds. Goodman & Gilman’s the pharmacological basis of therapeutics. 12th ed. New York: McGraw-Hill, 2011:481-525.
- Amato L, 2013, Cochrane Database Syst Rev, 2, CD003409
- Faggiano F, 2003, Cochrane Database Syst Rev, 3, CD002208
- Gowing L, 2011, Cochrane Database Syst Rev, 8, CD004145
- Mattick RP, 2008, Cochrane Database Syst Rev, 2, CD002207
Cited by
Committee Opinion No. 711: Opioid Use and Opioid Use Disorder in Pregnancy
(2017) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000002235 · Cited by 669
Opioid receptors: drivers to addiction?
Darcq, E., & Kieffer, B. L. (2018) · Nature Reviews Neuroscience · doi:10.1038/s41583-018-0028-x · Cited by 352
Macroeconomic conditions and opioid abuse
Hollingsworth, A., Ruhm, C. J., & Simon, K. (2017) · Journal of Health Economics · doi:10.1016/j.jhealeco.2017.07.009 · Cited by 312
Winkelman, T. N. A., Chang, V. W., & Binswanger, I. A. (2018) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.0558 · Cited by 301
Why aren't physicians prescribing more buprenorphine?
Huhn, A. S., & Dunn, K. E. (2017) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2017.04.005 · Cited by 291
Metadata
- Authors
- Schuckit, M. A.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Schuckit, Marc A.
- ORCID
- Schuckit, Marc A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2016-07-28
- Volume
- 375
- Issue
- 4
- Pages
- 357-368
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2496974376
- Cited by
- 540
- References
- 60
- Citations by year
- 2026: 19 · 2025: 32 · 2024: 34 · 2023: 40 · 2022: 43 · 2021: 71 · 2020: 77 · 2019: 102 · 2018: 70 · 2017: 46 · 2016: 5
- FWCI
- 10.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Opioid Use Disorder Treatment
- Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- opioid use disorder, opioid use disorder treatment, prescription opioid misuse, heroin, opioid overdose, naloxone, opioid antagonists, opioid agonists, buprenorphine, methadone maintenance treatment, naltrexone, sublingual buprenorphine, general practitioners, opioid prescribing, opioid epidemic, opioid-related deaths
- MeSH terms
- Adrenergic alpha-Agonists, Buprenorphine, Humans, Methadone, Opioid-Related Disorders, Substance Withdrawal Syndrome, Opiate Substitution Treatment
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Treatment of Opioid-Use Disorders. https://app.cochat.ai/papers/10.1056/nejmra1604339
- The paper
- Schuckit, M. A. (2016). Treatment of Opioid-Use Disorders. New England Journal of Medicine. https://doi.org/10.1056/nejmra1604339
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.